Astria Therapeutics Inc
ATXS6.830USD
+0.270+4.12%
Market hours （ET）Quotes delayed by 15 min
385.45MMarket Cap
LossP/E TTM
More Details of Astria Therapeutics Inc Company
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.
Company Info
Ticker SymbolATXS
Company nameAstria Therapeutics Inc
IPO dateJun 25, 2015
CEODr. Jill C. Milne, Ph.D.
Number of employees78
Security typeOrdinary Share
Fiscal year-endJun 25
Address22 Boston Wharf Road
CityBOSTON
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02210
Phone16173491971
Websitehttps://astriatx.com/
Ticker SymbolATXS
IPO dateJun 25, 2015
CEODr. Jill C. Milne, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
263.32K
--
Mr. Noah Clauser
Mr. Noah Clauser
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Higgins
Ms. Elizabeth Higgins
Investor Relations
Investor Relations
--
--
Dr. Joanne T. Beck, Ph.D.
Dr. Joanne T. Beck, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jill C. Milne, Ph.D.
Dr. Jill C. Milne, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Mr. Andrew Komjathy
Mr. Andrew Komjathy
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
--
--
Mr. Benjamin Scott Harshbarger
Mr. Benjamin Scott Harshbarger
Chief Legal Officer
Chief Legal Officer
--
--
Ms. Andrea Matthews
Ms. Andrea Matthews
Chief Business Officer
Chief Business Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
263.32K
--
Mr. Noah Clauser
Mr. Noah Clauser
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Higgins
Ms. Elizabeth Higgins
Investor Relations
Investor Relations
--
--
Dr. Joanne T. Beck, Ph.D.
Dr. Joanne T. Beck, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jill C. Milne, Ph.D.
Dr. Jill C. Milne, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Perceptive Advisors LLC
11.49%
RA Capital Management, LP
9.05%
Fidelity Management & Research Company LLC
8.52%
Vestal Point Capital, LP
7.41%
Forbion Capital Partners
6.77%
Other
56.77%
Shareholders
Shareholders
Proportion
Perceptive Advisors LLC
11.49%
RA Capital Management, LP
9.05%
Fidelity Management & Research Company LLC
8.52%
Vestal Point Capital, LP
7.41%
Forbion Capital Partners
6.77%
Other
56.77%
Shareholder Types
Shareholders
Proportion
Investment Advisor
32.69%
Venture Capital
23.81%
Hedge Fund
19.93%
Investment Advisor/Hedge Fund
16.86%
Private Equity
11.49%
Research Firm
1.00%
Individual Investor
0.49%
Pension Fund
0.21%
Bank and Trust
0.19%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
263
60.20M
106.68%
-10.73M
2025Q1
281
59.08M
104.77%
-12.46M
2024Q4
268
59.35M
105.17%
-9.44M
2024Q3
247
57.14M
101.27%
-10.09M
2024Q2
228
56.25M
102.41%
-8.30M
2024Q1
210
58.30M
106.65%
+7.30M
2023Q4
179
37.20M
102.69%
+9.26M
2023Q3
171
23.97M
88.11%
-4.33M
2023Q2
175
25.83M
94.82%
-888.95K
2023Q1
166
24.59M
91.65%
-670.60K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Perceptive Advisors LLC
6.49M
11.49%
--
--
Mar 31, 2025
RA Capital Management, LP
5.11M
9.05%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
4.81M
8.52%
-846.00K
-14.97%
Mar 31, 2025
Vestal Point Capital, LP
4.18M
7.41%
--
--
Mar 31, 2025
Forbion Capital Partners
3.82M
6.77%
+950.00K
+33.07%
Mar 31, 2025
Fairmount Funds Management LLC
3.55M
6.3%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.40M
6.03%
-66.23K
-1.91%
Mar 31, 2025
Millennium Management LLC
2.94M
5.21%
+1.30M
+79.78%
Jun 13, 2025
TCG Crossover Management, LLC
2.76M
4.89%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
2.64M
4.68%
-29.10K
-1.09%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
ALPS Medical Breakthroughs ETF
0.2%
iShares Micro-Cap ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Biotechnology ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
iShares Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.86%
ALPS Medical Breakthroughs ETF
Proportion0.2%
iShares Micro-Cap ETF
Proportion0.05%
ProShares Ultra Nasdaq Biotechnology
Proportion0.03%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
iShares Biotechnology ETF
Proportion0.02%
iShares Russell 2000 Value ETF
Proportion0.02%
Avantis US Small Cap Equity ETF
Proportion0.02%
iShares Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
Date
Type
Ratio
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
